Dr Kavita Mariwalla, highlights the multifaceted benefits of retinoid-based products in tackling diverse aspects of skin aging, shedding light on the often-underestimated potential of over-the-counter options, while also delving into the role of growth factors, particularly peptides, in skin aging prevention.
Kavita Mariwalla, MD, FAAD, discusses the importance of both preventing and reversing signs of skin aging, highlighting the role of ingredient layering, signaling peptides, and collagen production in maintaining youthful skin.
Chesahna Kindred, MD, MBA, FAAD, reviews the vitiligo support groups recommended for patients.
Renata Block, PA-C, and Gary M. Owens, MD, explore the access considerations for patients with vitiligo in special populations and review resources that clinicians and payers can share with patients with vitiligo.
Chesahna Kindred, MD, MBA, FAAD, examines how treatment can affect the quality of life in patients with vitiligo.
Dr Susan C. Taylor leads a discussion on newly approved agent, ruxolitinib, and its use in clinical practice as a targeted treatment option for patients with vitiligo.
Experts in dermatology comment on treatment approaches to vitiligo, including home phototherapy devices and recent autologous cell-harvesting technology for burn victims.
An expert in dermatology offers practice pearls and recommendations for the use of retinoid-based products in dermatology patient populations.
Dr Cheri N. Frey shares her insights into the mechanism of action of retinoid-based products and their efficacy in combating aging concerns such as fine lines and wrinkles.
Cheri N. Frey, MD, explores the evolution of retinoid-based skincare products, emphasizing novel formulations, molecules, and increased accessibility.
Gary M. Owens, MD, explains how an organization weighs the potential clinical outcomes for patients vs the cost of novel therapies for vitiligo.
Renata Block, PA-C, and Chesahna Kindred, MD, MBA, FAAD, explain how organizations addresses barriers to medication access [co-pay cards, patient coordinators] for novel vitiligo therapies.
Drs Susan C. Taylor and George Han highlight the importance of setting goals, managing patient expectations, and shared-decision making for vitiligo treatment.
Susan C. Taylor, MD, leads a discussion on approaching patient conversations on vitiligo including understanding patient lifestyle, cultural impact, and the impact on QoL.
Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.
Hilary Baldwin, MD, shares her thoughts on the importance of the Science of Skincare summit and emphasizes the significance of this event in disseminating clinically sound insights into over-the-counter active ingredients.
Gary M. Owens, MD, and Chesahna Kindred, MD, MBA, FAAD, discuss how an optimal multidisciplinary care model for patients with vitiligo can be achieved among providers, pharmacists, and payers.
Experts review the main adverse effects of ruxolitinib, how to monitor for them in your practice, and the key takeaways for clinicians and payers to know about the 2 phase 3 trials that led to the approval of ruxolitinib in vitiligo.
Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, share their approaches to educating patients on use of steroids for dermatologic conditions, highlighting how they approach pediatric patient populations.
Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.
Linda F. Stein Gold, MD; Jayme M. Heim, MSN, FNP-BC; and Darren West, MPAS, PA-C, review the adverse effect profiles of steroidal and nonsteroidal treatments, focusing on hypothalamic pituitary adrenal axis suppression.
Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, comment on how steroids continue to fit into the topical treatment armamentarium.
Experts in dermatological conditions review the different types of vitiligo and comment on distinguishing features that may be affected as well as differentiating from other hypopigmentation skin conditions.
Susan C. Taylor, MD, and George Han, MD, PhD, provide insight on disease awareness for vitiligo, patient demographics, and factors that contribute to vitiligo etiology.
Peter Lio, MD, reflects on current unmet needs in atopic dermatitis and suggests directions for future research and development.
Peter Lio, MD, shares findings and takeaways from a quantitative study designed to spotlight patient perceptions of current atopic dermatitis treatments and willingness to try new therapies.
Peter Lio, MD, explores the impact of atopic dermatitis on patient quality of life and how it shapes current and future treatment satisfaction.
Gary M. Owens, MD, explains how ruxolitinib fits into the treatment pathway for patients with vitiligo from a payer perspective.
Experts review which patients with vitiligo they would consider using ruxolitinib in.
